Literature DB >> 17468964

Rituximab in refractory MuSK antibody myasthenia gravis.

Mona Thakre, Jihad Inshasi, Mahmoud Marashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17468964     DOI： 10.1007/s00415-006-0442-2

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  5 in total

1.  Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.

Authors:  Berit Hain; Karin Jordan; Marcus Deschauer; Stephan Zierz
Journal:  Muscle Nerve       Date:  2006-04       Impact factor: 3.217

2.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

3.  Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.

Authors:  Amelia Evoli; Pietro A Tonali; Luca Padua; Mauro Lo Monaco; Flavia Scuderi; Anna P Batocchi; Mariapaola Marino; Emanuela Bartoccioni
Journal:  Brain       Date:  2003-06-23       Impact factor: 13.501

4.  Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report.

Authors:  Mark E Wylam; Peter M Anderson; Nancy L Kuntz; Vilmarie Rodriguez
Journal:  J Pediatr       Date:  2003-11       Impact factor: 4.406

Review 5.  The biology of CD20 and its potential as a target for mAb therapy.

Authors:  Mark S Cragg; Claire A Walshe; Andrey O Ivanov; Martin J Glennie
Journal:  Curr Dir Autoimmun       Date:  2005
  5 in total
  10 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.

Authors:  Richard J Nowak; Daniel B Dicapua; Nazlee Zebardast; Jonathan M Goldstein
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

Review 3.  Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.

Authors:  Panos Stathopoulos; Aditya Kumar; Jason A Vander Heiden; Elba Pascual-Goñi; Richard J Nowak; Kevin C O'Connor
Journal:  Ann N Y Acad Sci       Date:  2018-01       Impact factor: 5.691

Review 4.  Current and future standards in treatment of myasthenia gravis.

Authors:  Ralf Gold; Christiane Schneider-Gold
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 5.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

Authors:  Raffaele Iorio; Valentina Damato; Paolo Emilio Alboini; Amelia Evoli
Journal:  J Neurol       Date:  2014-10-12       Impact factor: 4.849

6.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

7.  Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.

Authors:  Enrico C Lallana; Camilo E Fadul
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

8.  Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.

Authors:  Sreenivasa Rao Sudulagunta; Mona Sepehrar; Mahesh Babu Sodalagunta; Aravinda Settikere Nataraju; Shiva Kumar Bangalore Raja; Deepak Sathyanarayana; Siddharth Gummadi; Hemanth Kumar Burra
Journal:  Ger Med Sci       Date:  2016-10-13

Review 9.  A New Classification System for IgG4 Autoantibodies.

Authors:  Inga Koneczny
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

Review 10.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.